PLRX

$1.08+$0.01 (+0.93%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$66.3M

62M shares

52-week range

$1.02 – $1.95

6% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-18.28

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$3M	-25.0%	$-1.39	$-1.42–$-1.37	—	3
2027	$8M	+200.0%	$-0.96	$-1.05–$-0.86	—	3
2028	$15M	+100.0%	$-0.83	$-1.42–$-0.30	—	3
2029	$15M	+0.0%	$-1.05	$-1.05–$-1.05	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.34	$-0.36	-5.3%
2026-05-11	$-0.36	$-0.32	+11.1%
2026-03-11	$-0.42	$-0.35	+16.7%
2025-11-06	$-0.53	$-0.43	+18.9%
2025-08-07	$-0.62	$-0.71	-14.5%
2025-05-08	$-0.78	$-0.92	-17.9%
2025-03-03	$-0.99	$-0.82	+17.2%
2024-11-07	$-0.99

DCF fair valuemodel estimate

Intrinsic value

$0.27

Price

$1.08

Implied downside

-75%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
PLRXPliant Therapeutics, Inc.	$1.07	+0.47%	$67M	—
ADVMAdverum Biotechnologies, Inc.	$4.36	+0.00%	$96M	—
ARTVArtiva Biotherapeutics, Inc.	$11.48	-0.43%	$561M	—
CLNNClene Inc.	$4.12	+1.11%	$53M	—
COYACoya Therapeutics, Inc.	$4.73	+0.85%

Pliant Therapeutics, Inc. Common Stock

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

www.pliantrx.com

Employees: 49
IPO / List date: Jun 3, 2020
HQ: SOUTH SAN FRANCISCO, CA

Held by traders on TradeandTell

No one on the platform currently holds PLRX.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	1,852,842	$2.3M

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded PLRX yet.

$PLRX chatter on StockTwits

Iron@ToTheMoonTTBearish11h
$PLRX easy short, Sub $1 is days away.
View on StockTwits ↗
Chris Luke@Lukey63Bullish18h
$PLRX Trading at 40% of cash and TBV and 2-yr runway. I am all-in as I have found such opportunities are usually fruitful.
View on StockTwits ↗
Biotech Pharma Investor@Biotech_Pharma_Investor2d
$PLRX 1st patient dosed April 30. It is already 3 full months since then and trial has been enroling faster than planned. First data shouldnt be too late in 2027. Maybe in AACR? (April 2027) or ASCO (June 2027) + new target indications to be announced within 2026. Best case scenario announcement comes with a PIPE/deal? Lots of things that can go well. Worst case scenario: not much news in 2026 + FORTIFY Trial data dissapoint and downside risk somwhat limited by cash cushion. Risk reward seems very favorable
View on StockTwits ↗
Biotech Pharma Investor@Biotech_Pharma_Investor2d
$PLRX - As of June 30, 2026, the Company had cash, cash equivalents and short-term investments of $159.6 million which the Company expects to be sufficient to fund operations into the second half of 2028. - Enrollment remains strong, progressing ahead of schedule. Interim data is expected in 2027. - Pliant plans to provide additional detail on the platform and path forward, including initial treatment indications, in the second half of 2026. Currently trading at around $66M valuation
View on StockTwits ↗
Biotech Pharma Investor@Biotech_Pharma_Investor2d
@buyandsold @LabPsycho @biotechpharmainvestor @Jpowll $PLRX too
View on StockTwits ↗
Earner Von Braun@EarnerVonBraunAug 5
$PLRX Reversal begins sometime between tomorrow, Thursday, and Monday next week.
View on StockTwits ↗
Iron@ToTheMoonTTBearishAug 2
$PLRX i shorted and expected to go lower.
View on StockTwits ↗
Gunnar@Gunnar1BullishJul 28
@BioRich In general, I agree. It's crucial to have a good entry here, so I'm scaling in here little by little. If you want, take a look into $OSTX , $AUTL , $PLRX and $UPB . I like all four for fundamental and technical reasons, Build my pos for the first three and now I'm scaling back into UPB after I sold 3 weeks ago in the mid 7's. I would appreciate your thoughts regarding these foru stocks. Greetings from Germany!
View on StockTwits ↗
Chucky@Chuckyboss1Jul 22
$PLRX 170 million in cash on hand here trading at 70 million market cap 100 million free money Wall Street bets and discord love these plays read there 10a
View on StockTwits ↗
VINCENT ETTER@PaulFrench1Jul 22
$PLRX One of my favorite biotech setups right now. From a technical perspective, I'm seeing a very promising chart: ✅ Two consecutive bullish Kijun-sen signals. ✅ Two consecutive bullish RSI divergences, suggesting that the long-term downtrend may be coming to an end as selling pressure continues to fade. The price has been building a solid base, and the current structure looks increasingly constructive. From a fundamental perspective, PLRX also stands out: • Strong cash position with an estimated runway of around 2 years. • Advanced clinical pipeline with several meaningful catalysts ahead. • Relatively low dilution risk compared to many small-cap biotech peers. • Overall financial risk appears limited. I only buy when technicals and fundamentals align, and PLRX is one of the few biotech names currently checking both boxes. Not financial advice just my opinion. Always do your own research. 😉
View on StockTwits ↗
Coffee Cake@SQUEAKSBANDITJul 21
$PLRX ugly an ATL with the xbi up today and near 52w highs there is simply no interest in this name really wish they would sell to tang or at least engage in conversation with him
View on StockTwits ↗
Gunnar@Gunnar1BullishJul 19
@Paulfrench I like your approach to look at fundamentals and technicals as well. I do the same for biotechs, and while I'm using other indicators at daily like KDJ, RSI, MACD and Keltner Channel, I'm coming to the same conclusion. That's the reason I scaled in last week at current level. So good luck to us... $PLRX
View on StockTwits ↗
VINCENT ETTER@PaulfrenchJul 19
$PLRX One of my favorite biotech setups right now. From a technical perspective, I'm seeing a very promising chart: ✅ Two consecutive bullish Kijun-sen signals. ✅ Two consecutive bullish RSI divergences, suggesting that the long-term downtrend may be coming to an end as selling pressure continues to fade. The price has been building a solid base, and the current structure looks increasingly constructive. From a fundamental perspective, PLRX also stands out: • Strong cash position with an estimated runway of around 2 years. • Advanced clinical pipeline with several meaningful catalysts ahead. • Relatively low dilution risk compared to many small-cap biotech peers. • Overall financial risk appears limited. I only buy when technicals and fundamentals align, and PLRX is one of the few biotech names currently checking both boxes. Not financial advice just my opinion. Always do your own research. 😉
View on StockTwits ↗
MaskMaker@MaskMakerBullishJul 19
$PLRX
View on StockTwits ↗
KA@ka1954Jul 15
$PLRX is this fucking going to stay dead forever? it seems like forever when i bought it
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.